---
title: "Analysis of Proteomes Data for Breast Cancer"

author:
- Group 14
- Alesia Olsen (s174584)
- Cathrine Lind (s184338)
- Mads Hartmann (s184284)
- Swati Tak (s220868)

fontsize: 12pt
theme: cerulean

date: '08 May 2022'
output: ioslides_presentation
---

```{r, include=FALSE}
knitr::opts_chunk$set(echo = TRUE, warning = FALSE, message = FALSE)
library(tidyverse)
library(kableExtra)
```

## Introduction

**Our dataset**: Breast Cancer Proteomes data from the Clinical Proteomic Tumor Analysis Consortium (NCI/NIH)

**Our aim**: To find meaningful biological insights, just like everybody else! And to have some learnings on the way.

## Materials: know our data

+-----------------------------------------------------+---------------------+---------------------+
| Dataset name                                        | Observations (rows) | Variables (columns) |
+=====================================================+=====================+=====================+
| Protein expression data                             | 12553               | 86                  |
|                                                     |                     |                     |
| *iTRAQ proteome profiling from 77 patients*         |                     |                     |
+-----------------------------------------------------+---------------------+---------------------+
| Clinical data                                       | 105                 | 30                  |
|                                                     |                     |                     |
| *Cancer classification of samples from 77 patients* |                     |                     |
+-----------------------------------------------------+---------------------+---------------------+

*Source: [Kaggle](https://www.kaggle.com/datasets/piotrgrabo/breastcancerproteomes)*

## Raw data

```{r, include = FALSE}
proteomes_raw <- read_csv(file = "../data/_raw/77_cancer_proteomes_CPTAC_itraq.csv")
clinical_raw <- read_csv(file = "../data/_raw/clinical_data_breast_cancer.csv")
```

**Raw Clinical Data** 105 observations and 30 variables

```{r, echo = FALSE}
clinical_raw %>% 
  select(0:6) %>%
  slice(0:4) %>% 
  kable() %>% 
  kable_styling(font_size = 9)
```

**Raw Proteome Data**: 12 553 observations and 86 variables

```{r, echo = FALSE}
proteomes_raw %>% 
  select(0:5) %>% 
  slice(0:4) %>% 
  kable() %>% 
  kable_styling(font_size = 9)
```

## Method: Cleaning data

![](/cloud/project/results/workflowClean.png){width="700"}

## Methods: Augmenting data
![](/cloud/project/results/WorkflowAugment.png){width="800"}

## Cancer subtypes in each age group

![](/cloud/project/results/barPlotcancersubtypedPAM50.png){width="800"}

**PAM50 test** usually categorizes cancer into 5 sub-types. But in our dataset, we found 4 sub-types only and we stuck to it.

## No. of tumors per cancer stage

![](/cloud/project/results/barPlotAJCCTumorAmount.png){width="800"}

**AJCC staging system**: American Joint Committee on Cancer's system to describe the amount and spread of cancer

## Principal components for proteomes

![](/cloud/project/results/pcaRotationMatrix.png){width="600" height="400"}

## Expression level variation

![](/cloud/project/results/HeatmapPAM50.png){width="670" height="500"}

## Discussion

1\. How different is the data for healthy individuals from unhealthy individuals?

2\. Can we target unhealthy individuals with specific different medicines in line with which cluster they are a part of?
